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worldwide. Some reports of cats with SARS-CoV-2 showed self-limiting respiratory or gastrointestinal
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In the present study, we investigated a cat with SARS-CoV-2 that was presented to a private animal
clinic in Northern Italy in May 2020 in a weak clinical condition due to an underlying intestinal B-
cell lymphoma. The cat developed signs of respiratory tract disease, including a sneeze, a cough and
ocular discharge, three days after an oropharyngeal swab tested positive for SARS-CoV-2 viral RNA
using two real-time reverse transcriptase polymerase chain reaction (RT-qPCR) assays for the envelope
(E) and RNA-dependent RNA polymerase (RdRp) gene. Thus, SARS-CoV-2 viral RNA was detectable
prior to the onset of clinical signs. Five and six months after positive molecular results, the serological
testing substantiated the presence of a SARS-CoV-2 infection in the cat with the detection of anti-SARS-
CoV-2 receptor binding domain (RBD) immunoglobulin (IgG) antibodies and neutralizing activity in
a surrogate virus neutralization assay (sVNT). To the best of our knowledge, this extends the known
duration of seropositivity of SARS-CoV-2 in a cat. Our study provides further evidence that cats are
susceptible to SARS-CoV-2 under natural conditions and strengthens the assumption that comorbidities
may play a role in the development of clinical disease.
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Abstract: Since the coronavirus disease (COVID-19) pandemic was first identified in early 2020, rare
cases of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in pet cats have
been reported worldwide. Some reports of cats with SARS-CoV-2 showed self-limiting respiratory or
gastrointestinal disease after suspected human-to-feline transmission via close contact with humans
with SARS-CoV-2. In the present study, we investigated a cat with SARS-CoV-2 that was presented to
a private animal clinic in Northern Italy in May 2020 in a weak clinical condition due to an underlying
intestinal B-cell lymphoma. The cat developed signs of respiratory tract disease, including a sneeze, a
cough and ocular discharge, three days after an oropharyngeal swab tested positive for SARS-CoV-2
viral RNA using two real-time reverse transcriptase polymerase chain reaction (RT-qPCR) assays
for the envelope (E) and RNA-dependent RNA polymerase (RdRp) gene. Thus, SARS-CoV-2 viral
RNA was detectable prior to the onset of clinical signs. Five and six months after positive molecular
results, the serological testing substantiated the presence of a SARS-CoV-2 infection in the cat with the
detection of anti-SARS-CoV-2 receptor binding domain (RBD) immunoglobulin (IgG) antibodies and
neutralizing activity in a surrogate virus neutralization assay (sVNT). To the best of our knowledge,
this extends the known duration of seropositivity of SARS-CoV-2 in a cat. Our study provides further
evidence that cats are susceptible to SARS-CoV-2 under natural conditions and strengthens the
assumption that comorbidities may play a role in the development of clinical disease.
Keywords: SARS-CoV-2; domestic cat; RT-qPCR; comorbidity; companion animal; B-cell lymphoma;
human-to-feline transmission; serology; neutralizing activity
1. Introduction
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has spread world-
wide among humans since the first cases were reported in January 2020 [1,2]. This novel
coronavirus (CoV), which can lead to the coronavirus disease-19 (COVID-19) in humans,
was presumably transmitted by animals, although the definitive animal origin has not yet
been confirmed [3–6]. After this initial zoonotic event, the pandemic is now sustained by
human-to-human transmission [7,8]. However, susceptibility has also been demonstrated
in domestic and wild animals under natural and experimental conditions [9–13]. Studies
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showed that pet cats are able to transmit SARS-CoV-2 to cohoused cats after experimental
virus inoculation [14–16], and in some reports, naturally infected cats developed clini-
cal signs of respiratory and/or gastrointestinal disease [17–21]. Comorbidities such as
hypertension, chronic kidney disease, diabetes mellitus and cancer were shown to in-
crease the risk of the development of severe symptoms in humans with COVID-19 [22,23].
These morbidities are also known as the most common diseases in geriatric feline pa-
tients [24]. Pet cats are popular companion animals and often live in close contact with
their owners. Especially in households affected by COVID-19, potential human-to-cat
transmission and subsequent symptomatic SARS-CoV-2 infection need to be surveilled
from a One-Health perspective.
Northern Italy was among the regions with the highest infection rates in the early
phase of the pandemic. The daily confirmed cases of SARS-CoV-2 infection in humans
peaked in Italy during the first wave at the end of March 2020, with around 6000 new
cases per day [25]. At that time, six veterinary clinics from Northern Italy contributed
to a SARS-CoV-2 surveillance study in collaboration with the Clinical Laboratory at the
Vetsuisse Faculty Zurich, University of Zurich, Switzerland. For this study, oropharyngeal
and nasal swabs from cats and dogs presented to the enrolled clinics were collected after
the owners were informed and gave written consent. The study was approved by the local
authorities and molecular, and subsequent serological testing was performed at the Clinical
Laboratory, Zurich.
Here, we report the case of a cat with SARS-CoV-2, which was presented in weak
clinical condition due to an underlying intestinal B-cell lymphoma. The cat developed
moderate signs of respiratory disease three days after SARS-CoV-2 RNA was detected
in RT-qPCR from an oropharyngeal swab. Anti-SARS-CoV-2 antibodies and neutralizing
activity confirmed infection and were still present at five and six months after the positive
RT-qPCR result. These findings support the urgent need for the surveillance of the role of
cats in the pandemic and the evaluation of health risks posed by SARS-CoV-2 infections in
cats, especially with underlying morbidities.
2. Case Report
A 12-year-old female spayed domestic short hair cat with no outdoor access was
presented at a small animal clinic in the Piedmont region of Northern Italy on 18 May 2020
with signs described as acute vomitus and diarrhea, weakness, tenesmus ani and weight
loss (Figure 1). The cat was already treated with the non-steroidal antiphlogistic drug
(NSAID) meloxicam (Metacam, Boehringer Ingelheim Vetmedica GmbH, Ingelheim/Rhein,
Germany) and the antibiotic cefovecin (Convenia, Zoetis, Parsippany, NJ, USA) by a private
veterinarian three days prior, due to the described tenesmus. The cat was referred to the
clinic after the onset of acute vomiting and diarrhea. The cat’s medical history indicated
it had suffered a traumatic hip fracture eight years prior and a thymectomy, with the
histologic diagnosis of thymoma recorded in 2018.
A clinical examination revealed that the cat weighed 3.9 kg and had a physiologic
body condition score of 5/9, a heart murmur with a degree of II/VI, and tenesmus ani. No
other abnormalities were found during the examination. For further assessment, complete
blood work, urinalysis, and diagnostic imaging were performed. Ethylenediamine tetra-
acetic acid (EDTA) anticoagulated blood for hematology and serum for biochemistry were
collected. Hematology showed a moderate normocytic normochromic anemia (hematocrit
24.8%, reference range 28.2–52.7%, red blood cell count (RBC) 5.6 T/L, reference range
7.1–11.5 T/L). A hypoalbuminemia (19 g/L, reference range 27–44 g/L) and a mild hy-
perglycemia (176 mg/dL, reference range 63–140 mg/dL) were found in the biochemistry
examination. All other measured biochemistry values were within the reference ranges.
On the same day, the cat was included in the multicentric study that aimed to evaluate
the prevalence of SARS-CoV-2 in domestic cats and dogs. An oropharyngeal and a nasal
swab were collected and stored in a prelabelled tube containing 300 µL of DNA/RNA
shield solution (Zymo Research Europe GmbH, Freiburg, Germany). The swab samples
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were stored at 4 ◦C and shipped at ambient temperature to the clinical laboratory for
further analysis.
Urinalysis was unremarkable, and thoracic radiographs showed an ill-defined area of
increased opacity (approximately 2.5 cm × 1.5 cm × 1.2 cm) in the caudo-dorsal part of
the right caudal lung lobe, which was already observed in 2018, and a diffuse bronchial
wall thickening. The abdominal ultrasound identified splenomegaly with a honeycomb
pattern and increased thickness of the intestinal muscular layer. A fine needle aspiration
(FNA) of the spleen was performed, and a subsequent cytological assessment showed an
increased number of lymphoid cells, a finding consistent with the differential diagnoses of
lymphoid hyperplasia or lymphoma. The FNA specimen was sent for further analysis by
polymerase chain reaction (PCR) for antigen receptor rearrangements (PARR), which later
confirmed the presence of a monoclonal B-cell receptor arrangement (IDEXX Laboratories
Inc., Westbrook, ME, USA). Based on the clinical findings and the PARR result, an intestinal
B-cell lymphoma was then diagnosed.
On 23 May 2020, the cat was brought in again for consultation after having developed
signs consistent with respiratory disease, especially sneezing, coughing and ocular dis-
charge, two days earlier (Figure 1). The administration of aerosolized physiologic saline
solution 0.9% was prescribed. At check-ups two and four days later, the cat continued to
sneeze and showed inappetence. The results of hematology were unremarkable, and the
clinical biochemistry revealed the persistence of hypoalbuminemia at 21 g/L (reference
range: 27–44 g/L). However, the respiratory signs were self-limiting and resolved four days
after the last check-up in May 2020. Additionally, at the same time as the cat showed signs
of respiratory disease, the owner was suspected to have COVID-19. Later in summer 2020,
the owner reported that a SARS-CoV-2 infection was confirmed by a positive SARS-CoV-2
antibody test. Additional information on the health status of the owner was not available.
The cohoused cat had shown respiratory clinical signs comparable to the cat reported
herein at the same time. However, samples from the cohoused cat and subsequent swab
samples from the here reported cat were unavailable.
 
Figure 1. Timeline of consultations at the veterinary clinic (top) and sample collection for SARS-CoV-2 diagnostics including
the results (bottom). Signs of respiratory disease (as indicated with the blue star) started three days after swab samples
were collected. Abbreviations: real time reverse transcriptase polymerase chain reaction (RT-qPCR), envelope gene (E gene),
RNA-dependent RNA polymerase gene (RdRp gene), receptor binding domain enzyme-linked immunosorbent assay
(RBD-ELISA), surrogate virus neutralization test (sVNT).
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Chemotherapy with lomustine 50 mg/m2 and prednisolone 2 mg/kg began on 9 June
2020. After two weeks, hematologic analysis revealed a neutropenia grade 2 (1162 cells/µL,
reference range: 2620–15170 cells/µL). However, the cat was in good clinical condition,
its body weight had increased, and no clinical signs compatible with infectious disease
were observed. Twenty-eight days after the previous administration, the cat was in good
condition, lomustine was administered at the same dosage and treatment continued every
28 days, except prednisolone administration was stopped after the first month.
As part of the SARS-CoV-2 surveillance study in companion animals, the oropha-
ryngeal and nasal swabs were analyzed in Zurich on 28 September 2020 using reverse-
transcriptase real-time polymerase chain reaction (RT-qPCR) as previously described [26].
Briefly, the total nucleic acids (TNA) were extracted from both swabs using a MagNA
Pure LC 2.0 instrument (Roche Diagnostics AG, Rotkreuz, Switzerland) with the MagNA
Pure LC Total Nucleic Acid—High Performance Kit (Roche Diagnostics AG). Subsequently,
4 µL of the sample TNA was used for a RT-qPCR with 20 µL of total reaction volume.
The reaction included a TaqMan® Fast Virus 1-Step Master Mix (Applied Biosystems,
Foster City, CA, USA) and targeted the envelope (E) or RNA-dependent RNA polymerase
(RdRp) gene. The oropharyngeal swab of the cat yielded RT-qPCR-positive results with an
amplification in the E and RdRp genes of SARS-CoV-2. The cycle threshold (CT) values
were high, with 39 in the E gene and 41 in the RdRp gene, and were, therefore, interpreted as
questionable positive [26]. The nasal swab tested negative for SARS-CoV-2 RNA. The result
from the oropharyngeal swab was confirmed as positive by the Swiss Federal Institute
for Virology and Immunology (IVI, Mittelhäusern, Switzerland), with CT values ranging
from 36.6 to 37.2 in RT-qPCR assays targeting the E and RdRp genes of SARS-CoV-2 [27].
Results with a CT value ≤38 are considered positive. Both swabs were analyzed for the
presence of feline calicivirus (FCV) and feline herpesvirus (FHV) nucleic acids by RT-qPCR
and qPCR [28,29], respectively, yielding negative results.
Thereafter, the cat was presented to the clinic for the monthly application of chemother-
apy (14 October 2020 and 16 November 2020) and was in good clinical condition. The
hematology and biochemistry were unremarkable. The remains of the collected blood
(EDTA plasma and serum) were sent for serological testing to the clinical laboratory in
Switzerland. Two serological tests were performed for the detection of anti-SARS-CoV-2
antibodies. An in-house established enzyme-linked immunosorbent assay (ELISA), which
detects immunoglobulins G (IgG) against the receptor binding domain (RBD) of the viral
spike protein S1 domain, was conducted with the patient’s EDTA plasma and serum as
previously described [26]. Briefly, a 96-well MICROLON®, C-bottom, medium binding
plate (Greiner-Bio One, St. Gallen, Switzerland) was coated with 200 ng/well of recombi-
nant spike glycoprotein RBD SARS-related Coronavirus 2, Wuhan-Hu-1 with C-Terminal
Histidine Tag (NR-52946, BEI Resources, Manassas, United States). Samples and controls
were heat inactivated and diluted at 1:100 with P3x buffer, which contains 0.15 M sodium
chloride, 1 mM Na2-EDTA (Titriplex
® III, VWR, Dietikon, Switzerland), 0.05 M Tris-base
(tris(hydroxymethyl)aminomethane, Fisher Scientific, Rheinach, Switzerland), 0.1% bovine
serum albumin (BSA) and 0.1% Tween 20. For each reaction, 100 µL of diluted samples
or controls was used and pipetted in duplicate. Twenty-four pre-COVID sera from Swiss
cats collected before January 2020 and four positive control sera were run in parallel as
previously described [26]. The positive control sera were provided by Dr Herman Egberink
and Dr Els Broens, Faculty of Veterinary Medicine, University of Utrecht, the Netherlands.
The plasma sample from 14 October 2020 and the serum sample from 16 November 2020
yielded positive results in the ELISA with mean optical density (OD) values of 1.07 and
1.12, respectively (Figure 2a). For this assay, the positive cut-off was set at six-fold standard
deviations above the mean OD of pre-COVID sera at 0.78 [26,30].







Figure 2. Serological results from blood collected in October and November 2020. Positive controls (n = 4) and pre-COVID
sera (n = 24, collected before 5 January 2020) were run in parallel in both assays. (a) Enzyme-linked immunosorbent assay
(ELISA) for the detection of anti-SARS-CoV-2 spike protein receptor binding domain (RBD) antibodies. Results are presented
by optical density values (OD) and were measured at 415 nm. The mean OD is shown as a line within the group. The
dotted line shows the positive cut-off value set at 0.78. (b) A surrogate virus neutralization test (sVNT) was used to measure
neutralizing activity. The dashed line indicates the positive cut-off set for human samples by the manufacturer at ≥20%,
and the dotted line indicates the positive cut-off calculated at 81.8%.
The neutralizing activity in the plasma was measured with the commercially available
surrogate virus neutralization test kit (sVNT, GenScript Inc., Piscataway, NJ, USA). In this
test, the inhibition of the binding of the viral spike glycoprotein RBD to an angiotensin
converting enzyme-2 (ACE2) cell surface receptor is assessed independent of species
identity. The test was conducted according to the manufacturer’s instructions. Negative
and positive controls provided by the kit were run in parallel and the measured OD
values ranged within the required references to assure test validity. Together with the
samples, 24 pre-COVID sera and four positive control sera were analyzed. According to the
manufacturer’s directions, an inhibition of ≥20% is stated as positive for human samples.
As reported earlier, we calculated a positive cut-off as six-fold standard deviation above the
mean inhibition of the pre-COVID sera, which was set at 81.8% [26]. The cat’s plasma from
14 October 2020 and the serum from 16 November 2020 both yielded positive inhibition
measurements of 99.9 and 100.5%, respectively (Figure 2b).
For confirmation of the detected antibody response, the plasma from 14 October 2020
was sent to the Virology Division of the Faculty of Veterinary Medicine, University of
Utrecht where seropositivity was verified with a virus neutralization assay with vesicular
stomatitis virus (VSV) particles pseudotyped with SARS-CoV-2 spike protein [31,32] and
yielded a titer of 1:256 (a titer ≥16 is considered positive).
The serum sample from 16 November 2020 was also tested for feline immunodeficiency
virus (FIV) using Western blot and feline leukemia virus (FeLV) p27 antigen by sandwich
ELISA as previously described [33–36]. Both tests yielded negative results. No samples
were available from the cohoused cat.
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3. Discussion
We hereby report the case of a 12-year-old female spayed domestic shorthair cat with
SARS-CoV-2, which developed moderate signs of respiratory disease, while exhibiting a
weak clinical condition due to an underlying intestinal B-cell lymphoma. An oropharyngeal
swab, collected shortly before the cat developed signs of respiratory disease, yielded
positive results for SARS-CoV-2 in RT-qPCR in the E and RdRp gene. The measured CT-
values, which ranged from 36.6 to 41 depending on the performed assay and targeted
gene, reflected low viral RNA loads. These low viral RNA loads may be explained by the
early timepoint of sampling, three days before the onset of signs of respiratory disease.
Sequencing of the viral RNA was not attempted due to the low viral RNA loads, and no
subsequent swab samples were available for further investigation of viral RNA shedding.
The swab samples tested negative for common feline respiratory viral agents (FCV and
FHV) and no evidence of FIV or progressive FeLV infection was detected in the cat. Given
that other common feline viral infections were excluded, we assume that the SARS-CoV-2
infection played a role in the development of respiratory disease in the cat. At the same
time, the cat owner experienced symptoms compatible with SARS-CoV-2 infection, which
was later confirmed by a serological test. In May 2020, the daily confirmed new SARS-CoV-
2-positive cases for humans in Italy had declined: in the region of Piedmont, there were
9874 total active cases and 72 new cases noted on 18 May 2020 [37].
Six months after the SARS-CoV-2 viral RNA-positive oropharyngeal swab was col-
lected, serological tests confirmed SARS-CoV-2 infection in the cat by the detection of
anti-SARS-CoV-2 spike protein RBD-antibodies and neutralizing activity in an ELISA-
based surrogate virus neutralization test. Between the fifth and sixth month, the antibody
response remained unchanged. This further strengthens the assumption that the cat had
become infected at the timepoint of the detection of viral RNA and the onset of respiratory
signs and antibodies to SARS-CoV-2 were still present six months later. This seems to be the
longest time span to date that the immune response to SARS-CoV-2 infection in a pet cat
was detectable. A recent report demonstrated that antibodies in naturally infected pet cats
persist as long as two months [38]. A large-scale surveillance study, which was conducted
from March to May 2020 with samples collected mostly in Lombardy, a neighboring region
of Piedmont, reported no PCR-positive cats (0/180, including 57 cats from previously con-
firmed households affected by COVID-19 and 38 cats with respiratory signs), but detected
neutralizing antibodies in 5.8% (11/191) of the tested cats [39].
Since the pandemic was first identified in 2020, small numbers of SARS-CoV-2 in-
fections in cats under natural conditions have been reported. In almost all of these cases,
human-to-animal transmission was suspected, and to date, no zoonotic events involving
infected cats have been described [13]. However, proof of cat-to-human SARS-CoV-2
transmission will unlikely be obtainable, for ethical and study design considerations [40].
By contrast, animal-to-human transmission was shown at infected mink farms [11,41–43].
In cats, clinical disease accompanied with natural SARS-CoV-2 infection could be observed
in some cases, with cats showing respiratory and/or gastrointestinal signs [13,20,44,45].
Notably, most cats that were infected under experimental conditions did not develop
clinical signs, although viral shedding was present from day one up to day seven post
infection [14–16,46]. However, only cats without underlying health impairments were
included in experimental studies, unlike the pet cat population presented to veterinarians.
Human patients with underlying clinical conditions or immunocompromised humans
were shown to have a higher risk of developing severe clinical disease when infected with
SARS-CoV-2 [22,23], and a previous report from Spain in felines suspected the contribu-
tion of comorbidities to the clinical outcome in a cat that was found to be SARS-CoV-2
RT-qPCR positive using nasal swabs while suffering from severe respiratory distress and
thrombocytopenia. After the cat was euthanized and a necropsy had been conducted, the
cat was diagnosed with feline hypertrophic cardiomyopathy, severe pulmonary edema
and thrombosis [18]. Here, we described the case of a cat with symptomatic SARS-CoV-2
infection while suffering from intestinal B-cell lymphoma.
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In many countries, the molecular detection of SARS-CoV-2 in pets is currently limited to
research studies or, in the case of diagnostic purposes, is restricted to specific regulations, such
as contact with humans with SARS-CoV-2 and the development of clinical disease potentially
related to SARS-CoV-2 infection. Therefore, the prevalence of SARS-CoV-2 infection in
cats, especially asymptomatic cases, may be underestimated [38]. However, SARS-CoV-2
diagnostics in cats living in critical environments, such as residencies for elderly people, dense
housing conditions and cat rescue and breeding facilities, are of importance. Furthermore, the
recently emerged variants (B.1.1.7. and B.1.351) may have a fitness advantage associated with
mutations in the spike protein, which are suspected to lead to an increase in human-to-human
transmissibility and more effective replication [47,48]. Possible changes in the susceptibility of
animals, in the context of these new variants, should be evaluated.
As part of infection prevention, humans with SARS-CoV-2 should limit close contact
with animals and apply strict hygiene measures, similar to those implemented when in
contact with uninfected humans [49]. Such hygiene measures for pet owners include
“handling animals only when wearing a mask, washing their hands with soap and water
for at least 20 s before and after being near or handling their animals, their food, or their
supplies, as well as avoiding kissing their pets or sharing food, towels, or the bed with
them”, as recommended by the European Advisory Board on Cat Diseases (ABCD) [50,51].
This novel viral infection has proven its potential for interspecies transmission and
zoonosis. A SARS-CoV-2 infection presents a health risk to cats, which may be increased by
comorbidities. Thus, SARS-CoV-2 needs to be closely surveilled in the human–animal interface.
4. Conclusions
The current case adds important information to the field, as SARS-CoV-2 infection
was detected in a cat in poor condition due to an underlying intestinal B-cell lymphoma
and three days before the onset of respiratory signs. Seropositivity was present for at least
half a year after the oropharyngeal swab from this cat tested positive for SARS-CoV-2
RNA. Further investigations in susceptibility, immunity and the role of comorbidities as
promotive factors for SARS-CoV-2-related disease in cats are essential.
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